IQV

IQVIA Holdings Inc

IQV, USA

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. It has a strategic collaboration with Sarah Cannon Research Institute to enhance clinical trial processes. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is based in Durham, North Carolina.

https://www.iqvia.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
IQV
stock
IQV

Bellevue Group AG Sells 27,368 Shares of IQVIA Holdings Inc. $IQV MarketBeat

Read more →
IQV
stock
IQV

IQVIA: Increasingly Indispensable In Drug Development (NYSE:IQV) Seeking Alpha

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$247.5

Analyst Picks

Strong Buy

14

Buy

2

Hold

7

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Medium

31.64

Low 50

High 10

Price to Book Ratio (P/B)

-

Very High

6.20

Low 1

High 3

Return on Equity (ROE)

-

Very Low

5.37 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

1.15 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

15.00 %

Low 5%

High 15%

Debt to Equity

-

Very Low

3.64

Low 1

High 0.3

Investors

* Institutions hold a combined 21.65% of the total shares of IQVIA Holdings Inc

1.

Vanguard Total Stock Mkt Idx Inv

(3.0391%)

since

2025/07/31

2.

Vanguard 500 Index Investor

(2.3932%)

since

2025/07/31

3.

Vanguard Mid Cap Index Institutional

(2.1565%)

since

2025/07/31

4.

Oakmark Investor

(1.6196%)

since

2025/06/30

5.

Oakmark Select Investor

(1.5647%)

since

2025/06/30

6.

Fidelity 500 Index

(1.2255%)

since

2025/07/31

7.

SPDR® S&P 500® ETF

(1.1705%)

since

2025/08/31

8.

iShares Core S&P 500 ETF

(1.1633%)

since

2025/08/31

9.

Vanguard Value Index Inv

(0.8568%)

since

2025/07/31

10.

The Health Care Select Sector SPDR® ETF

(0.6602%)

since

2025/08/31

11.

iShares Biotechnology ETF

(0.6017%)

since

2025/08/31

12.

Vanguard Institutional Index I

(0.584%)

since

2025/07/31

13.

Pacer US Cash Cows 100 ETF

(0.546%)

since

2025/08/29

14.

Invesco S&P 500® Equal Weight ETF

(0.524%)

since

2025/08/29

15.

State St S&P 500® Indx SL Cl III

(0.516%)

since

2025/08/31

16.

JPMorgan Mid Cap Value L

(0.5085%)

since

2025/07/31

17.

Deutsche Bank AG

(0.5075%)

since

2025/06/30

18.

American Funds IS® Growth-Income 1

(0.5067%)

since

2025/06/30

19.

Capital Group Core Equity Composite

(0.5067%)

since

2025/06/30

21.

JPM US Mid Cap Value-Composite

(0.4987%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

3.39

Latest Release

Date

2025-09-30

EPS Actual

3

EPS Estimate

2.97

EPS Difference

0.03

Surprise Percent

1.0101%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(6.3)
GARP
Fair GARP(4.5)
Growth
Moderate Growth(4.5)
Momentum
Moderate Momentum(5.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(4.5)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.